Asthma is one of the most common chronic conditions in the United States, and one of the most under-treated. Asthma symptoms are the surface of an inflammatory process that continues between attacks, and relieving the squeeze without treating the inflammation leaves the disease running underneath.
That is the biggest change in modern asthma care: guideline bodies no longer recommend treating adults and adolescents with a short-acting reliever inhaler alone. Below: what an attack feels like, which signs mean call 911, how asthma is diagnosed, why two people with the same label need different medicines, and what blood work can and cannot tell you.
What is asthma?
Asthma is a chronic airway disease defined by two features occurring together: inflammation of the airway lining, and variable airflow obstruction. The lining swells and produces excess mucus, while the muscle around those tubes contracts too readily, a property called bronchial hyperresponsiveness. The channel air travels through narrows, and moving air out becomes harder than moving it in.
The word “variable” carries the diagnostic weight. Airflow changes over hours, days and seasons, which separates asthma from fixed obstruction and explains why someone can feel normal in clinic and struggle at 3 a.m. A normal exam does not rule asthma out. Adult-onset asthma is common, less allergic, more persistent, and often missed for years.
Symptoms and what an attack feels like
The four cardinal symptoms are wheezing, shortness of breath, chest tightness and cough. They cluster, worsen at night or early morning, and follow a trigger such as exercise, cold air, an allergen or an infection. A cough that lingers for weeks after a cold or wakes you at night is a classic, frequently overlooked presentation.
Chest tightness is often described as a band around the ribs, and the difficulty is in getting air out. An attack, or exacerbation, is a progressive worsening over minutes to days: the reliever helps less and for less time, and stairs become hard. Frequent attacks signal that the underlying inflammation is not treated adequately.
Red flags that mean call 911
Call 911 immediately if any of these are present. They are emergency signs, not reasons to wait and see.
- The reliever is not working, or relief wears off and symptoms return within a few hours.
- You cannot speak in full sentences and have to break to breathe every few words.
- Lips, face or fingernails turn blue, grey or dusky.
- Drowsiness or confusion. Someone who becomes quiet and sleepy while severely breathless is deteriorating, not calming down.
- In a child, the skin pulling in between the ribs, at the base of the neck or under the breastbone with each breath, plus nostril flaring or inability to talk.
A silent chest, where wheezing stops but breathing is clearly labored, is also an emergency: too little air is moving to make noise. While waiting for help, sit upright and use the reliever as directed in your action plan. Call 911 rather than driving yourself.
Triggers
Triggers do not cause asthma; they provoke symptoms in airways already inflamed. Identifying your own is worthwhile, because avoidance costs nothing.
| Trigger category | Examples | Practical note |
|---|---|---|
| Indoor allergens | Dust mites, pet dander, cockroach, indoor mold | Mattress encasements and humidity below 50 percent beat purifiers. |
| Outdoor allergens | Tree, grass and weed pollen; mold spores | Seasonal patterns are predictable, allowing pre-season review. |
| Respiratory infections | Colds, influenza, RSV, sinusitis | Viruses are the leading cause of attacks; annual flu vaccination is standard. |
| Irritants | Tobacco smoke, vaping aerosol, wildfire smoke, cleaning sprays | These act on airway nerves directly; no allergy is needed. |
| Exercise and cold air | Winter running, intervals, chlorinated pools | Exercise symptoms usually mean controller therapy is inadequate. |
| Occupational and drug exposures | Flour, isocyanates, latex, wood dust; NSAIDs | Improvement on weekends is the clue; nasal polyps plus NSAID reactions need specialist input. |
Asthma phenotypes: why two people need different treatment
Asthma is an umbrella term for several biological patterns. The most useful division is type 2 versus non-type-2 inflammation.
Type 2 asthma, often called eosinophilic or T2-high, is driven by interleukin-4, interleukin-5 and interleukin-13 signaling. It typically shows raised eosinophils, raised exhaled nitric oxide and often raised IgE. This group frequently carries companion conditions from the same immune family, such as nasal polyps and atopic dermatitis with a lifelong allergic trajectory. It responds well to inhaled corticosteroids and is the phenotype most current biologics target.
Non-type-2 asthma covers everything else: neutrophilic, paucigranulocytic, obesity-associated and smoking-related. Eosinophils and exhaled nitric oxide are normal or low, steroid response is less predictable, and targeted options are fewer, so management leans on bronchodilator optimization, weight loss and smoking cessation. Recognizing this group prevents escalating steroids indefinitely in disease that was never steroid-responsive.
Causes and risk factors
No single cause explains asthma. It emerges when genetic susceptibility meets environmental exposure, usually early in life, and dozens of gene variants affecting airway lining and immune signaling have been identified, none deterministic.
Atopy, the inherited tendency to make IgE against ordinary proteins, is the strongest single predictor of childhood asthma. Many children follow the atopic march: infant eczema, then seasonal allergic rhinitis that arrives in the preschool years, then asthma. Other contributors include prematurity, severe infant bronchiolitis, maternal smoking, secondhand smoke and vaping aerosol, air pollution, obesity and occupational sensitizers. A smoker with months of productive cough may instead have chronic bronchitis producing fixed rather than variable obstruction.
How asthma is diagnosed
Asthma is diagnosed by documenting variable airflow obstruction in someone with a compatible history. A substantial share of adults carrying the label turn out on testing not to have it.
Spirometry with bronchodilator reversibility is the reference test: you blow into a machine measuring forced expiratory volume in one second (FEV1) and forced vital capacity. A reduced FEV1 to FVC ratio shows obstruction, and a meaningful FEV1 improvement after a bronchodilator shows reversibility. Peak flow monitoring at home for one to two weeks demonstrates variability when clinic spirometry is normal. Fractional exhaled nitric oxide (FeNO) estimates type 2 inflammation and supports eosinophilic asthma when raised, though a normal value does not exclude asthma. Methacholine or exercise challenge testing is reserved for convincing symptoms with normal spirometry.
Blood tests that matter, and what they actually tell you
Be clear: no blood test diagnoses asthma. Spirometry with reversibility does. Blood work characterizes the phenotype, guides drug selection and rules out mimics.
The blood eosinophil count is the workhorse. Eosinophils are white cells recruited by interleukin-5 signaling, and a raised count identifies the type 2 pattern predicting response to inhaled corticosteroids and anti-interleukin-5 biologics. Severe asthma clinics check an eosinophil count that identifies type 2 airway inflammation before choosing a targeted drug. Counts fall sharply during oral steroid courses, so timing changes the result.
Total IgE and specific IgE map the allergic component: total IgE with body weight sets eligibility for anti-IgE therapy, while specific IgE confirms which exposures matter. Clinicians also order a complete blood count that places the eosinophil value in context, since anemia can explain breathlessness on its own. Counts far beyond the usual asthma range prompt a search for parasitic infection or eosinophilic granulomatosis with polyangiitis.
Vitamin D deficiency is common in poorly controlled asthma and has been studied as a modifier of exacerbation risk, so many clinicians check a vitamin D level that flags a correctable deficiency. None of these results makes the diagnosis.
Treatment: what has changed
The most important update in a generation concerns the reliever inhaler. For decades, mild asthma was treated with a short-acting beta-agonist (SABA) alone, as needed. That is no longer recommended for adults and adolescents. A SABA opens the airway for a few hours and does nothing to the inflammation underneath, so the disease progresses while the person feels better, and heavy reliever use is linked to worse control and severe attacks.
Guidelines now recommend that essentially every adult and adolescent with asthma receive a reliever containing an inhaled corticosteroid, so each rescue dose delivers anti-inflammatory treatment exactly when inflammation flares. Two approaches exist: an inhaled corticosteroid with formoterol used as both maintenance and reliever, and a fixed albuterol-plus-corticosteroid combination used as needed. If you were handed a blue inhaler years ago and never had it reviewed, book that conversation with your prescriber, and do not stop, swap or adjust any inhaler on your own.
Controller therapy remains built around inhaled corticosteroids, escalated with a long-acting beta-agonist and, at higher steps, a long-acting muscarinic antagonist. Leukotriene receptor antagonists are an alternative, carrying a neuropsychiatric warning, and allergen immunotherapy suits selected allergic patients. Oral corticosteroids treat attacks but carry cumulative harm and signal inadequate control.
For severe asthma uncontrolled on high-dose inhaled therapy, biologics target specific pathways: anti-IgE for allergic asthma, anti-interleukin-5 agents for eosinophilic asthma, anti-interleukin-4-receptor for type 2 disease, and anti-TSLP further upstream. Phenotype markers drive that choice, which is why the blood tests above come first.
Finally, inhaler technique. Poor technique is one of the most common reasons asthma treatment appears to fail, and a large share of patients make at least one critical error: not exhaling fully first, firing the canister before starting the breath, or skipping the breath hold. Using a spacer and asking a pharmacist to check your technique at every review fixes more asthma than most dose increases.
Conditions that make asthma harder to control
When asthma resists treatment, look for a companion condition before escalating drugs. Allergic rhinitis and rhinosinusitis with nasal polyps sit in the same pathway, and treating the upper airway improves the lower one. Many hard-to-control patients have acid reflux that worsens nocturnal breathing symptoms. Obesity alters lung mechanics and reduces steroid responsiveness, and weight loss measurably improves control. Sleep apnea, anxiety, vocal cord dysfunction, smoking and non-adherence complete the list, along with influenza that can trigger a severe asthma exacerbation.
Living with asthma: action plans and daily management
Everyone with asthma should have a written action plan agreed with a clinician. A good plan uses green, yellow and red zones based on symptoms and peak flow, specifying what to take when stable, what to do when symptoms worsen, and when to seek emergency care. Specific plans reduce hospitalizations.
Beyond the plan: take controller therapy daily even when you feel well; get an annual flu vaccination; stop smoking and vaping; keep exercising, because fitness improves outcomes and exertional symptoms indicate a treatment gap rather than a reason to stop; and attend reviews where technique and reliever use are checked. Needing your reliever more than twice a week, or waking at night from asthma, signals inadequate control.
Latest scientific advances
The 2023 FDA approval of a combined albuterol-and-inhaled-corticosteroid rescue inhaler rested on the MANDALA trial, and a later analysis examined how patients used it. Researchers reviewed diary data from 981 patients on as-needed albuterol-budesonide and 981 on as-needed albuterol alone. Use patterns were nearly identical, averaging 2.6 inhalations per day with the combination and 2.8 with albuterol alone, and adverse event rates were low and comparable (Chipps et al., 2025). What this means for you: an inhaled corticosteroid in the rescue inhaler treats inflammation during a flare without changing how often you reach for it.
For severe disease, a systematic review and meta-analysis pooled 48 randomized controlled trials covering 16,350 patients treated with licensed asthma biologics, including tezepelumab. Biologics cut the annualized rate of asthma attacks by 44 percent (rate ratio 0.56) and hospitalizations by 60 percent (rate ratio 0.40), and improved FEV1 by an average of 0.11 liters. Effects were consistently greater in patients with markers of type 2 inflammation such as raised blood eosinophils and FeNO (Kyriakopoulos et al., 2024). What this means for you: in severe asthma, the biomarkers in your blood and breath predict how much a targeted drug is likely to deliver.
Dosing intervals are lengthening. In two replicate phase 3 placebo-controlled trials, an ultra-long-acting anti-interleukin-5 antibody injected twice a year was tested in 762 patients with severe eosinophilic asthma. Over 52 weeks the annualized exacerbation rate fell from 1.11 with placebo to 0.46 with the drug in the first trial (rate ratio 0.42), and from 1.08 to 0.56 in the second (rate ratio 0.52) (Jackson et al., 2024). What this means for you: severe eosinophilic asthma may increasingly be controlled with two appointments a year.
Myths and facts
| Myth | Fact |
|---|---|
| A rescue inhaler alone is enough if symptoms are mild. | Reliever-only treatment with a short-acting beta-agonist is no longer recommended for adults and adolescents; it leaves inflammation untreated. |
| Children outgrow asthma. | Symptoms often quiet in adolescence, but airway hyperresponsiveness persists and asthma can return. |
| People with asthma should avoid exercise. | Exercise improves outcomes; exertional symptoms mean treatment needs review. |
| A blood test can diagnose asthma. | Blood tests define phenotype and guide drug choice. Diagnosis requires spirometry showing reversible airflow obstruction. |
Glossary
| Term | Meaning |
|---|---|
| Bronchial hyperresponsiveness | Airway muscle contracting too readily to ordinary stimuli. |
| Exacerbation | An asthma attack: progressive worsening requiring a treatment change. |
| FEV1 | Forced expiratory volume in one second, measured on spirometry. |
| FeNO | Fractional exhaled nitric oxide, a breath test estimating type 2 airway inflammation. |
| Eosinophil | A white blood cell central to type 2 inflammation; a key phenotype marker. |
| SABA | Short-acting beta-agonist, a fast bronchodilator with no anti-inflammatory effect. |
| Spacer | A holding chamber on an inhaler that improves delivery to the lungs. |
Frequently asked questions
What does an asthma attack feel like?
Most people describe a tightening band around the chest, a struggle to push air out rather than pull it in, and a whistle on the exhale. Speech becomes clipped, the cough turns dry, and breathing becomes exhausting. Symptoms usually build over minutes to hours, often at night. If a reliever stops helping, if you cannot finish a sentence, or if lips or nails turn blue, call 911.
How is asthma diagnosed?
Diagnosis combines a symptom history with objective proof of variable airflow obstruction. Spirometry before and after a bronchodilator is the main test: it shows obstruction, then shows that obstruction reversing. Peak flow diaries kept for one to two weeks demonstrate variability when clinic spirometry looks normal, and a challenge test is used when the picture stays unclear. FeNO and blood tests define the phenotype rather than the diagnosis.
Is asthma genetic?
Genetics contribute substantially without determining the outcome. A parent or sibling with asthma raises your risk, and many gene variants affecting airway lining and immune signaling have been linked to it, none causing asthma alone. Environment does the rest: early respiratory infections, tobacco smoke, air pollution, allergens and obesity all shift risk. That is why asthma appears in people with no family history and skips children in affected families.
Can asthma be cured?
There is no cure, but asthma is highly controllable. With appropriate inhaled anti-inflammatory therapy, trigger management and good inhaler technique, most people achieve minimal symptoms, normal activity and no attacks. Childhood symptoms often fade in adolescence, though the underlying airway sensitivity commonly persists. The realistic goal is sustained control on the lowest effective treatment, reviewed regularly rather than left unchanged for years.
What are the signs of asthma in adults?
Adult asthma presents less dramatically than in children. Watch for a cough persisting weeks after a cold, breathlessness out of proportion to your fitness, chest tightness on cold mornings, intermittent wheeze, and waking at night to cough. Repeated bronchitis diagnoses in an adult non-smoker should prompt spirometry. Adult-onset asthma is often non-allergic, more persistent and more likely to become severe, so early testing matters.
Sources
- CDC — Asthma — Centers for Disease Control and Prevention, 2025 — cdc.gov
- National Heart, Lung, and Blood Institute — Asthma — NIH, 2025 — nhlbi.nih.gov
- MedlinePlus — Asthma — National Library of Medicine, 2025 — medlineplus.gov
- Global Initiative for Asthma — Global Strategy for Asthma Management — GINA, 2025 — ginasthma.org
- Chipps BE, et al. — Albuterol-budesonide rescue inhaler for asthma: patterns of use and safety in MANDALA — Annals of Allergy, Asthma & Immunology, 2025 — doi.org
- Kyriakopoulos C, et al. — Biologic agents licensed for severe asthma: systematic review and meta-analysis — European Respiratory Review, 2024 — doi.org
- Jackson DJ, et al. — Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype — New England Journal of Medicine, 2024 — doi.org
Further reading
- A cough that follows a cold and clears in a few weeks usually reflects acute bronchitis that resolves without antibiotics.
- Anyone with asthma who develops fever and chest pain should learn the pneumonia warning signs that require urgent assessment.
- Facial pressure and congestion alongside wheeze may point to a sinus infection that keeps the upper airway inflamed.
- Parents tracking an itchy rash with wheeze can review the eczema patterns that often precede childhood asthma.
Understand your lab results with BloodSense
Asthma treatment increasingly depends on numbers rather than labels. Your eosinophil count, total and specific IgE, complete blood count and vitamin D level together indicate whether your asthma is type 2 or non-type-2, which explains why one person thrives on an inhaled corticosteroid while another needs a different strategy. They also decide which biologic is likely to work in severe asthma.
Most people receive these results as a column of numbers with a reference range and no explanation of what the pattern means. BloodSense reads your lab report and explains each marker in plain language and in context, so you arrive at your next appointment able to ask better questions. It does not diagnose asthma.
